An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of ALIMTA versus docetaxel for other than predominantly squamous histologies (n=399, 9.3 versus 8.0 months, adjusted HR = 0.78; 95% CI =0 .61-1.00, p =0.047) and was in favour of docetaxel for squamous cell carcinoma histology (n=172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI =1.08-2.26, p =0.018).
13 lamerakulised histoloogiad (n=399; 9, 3 versus 8, 0 kuud, korrigeeritud HR = 0, 78; 95% CI = 0, 61... 1, 00; p=0, 047), kusjuures lamerakk- kartsinoomi histoloogia korral oli eelis dotsetakseeli kasuks (n=172; 6, 2 versus 7, 4 kuud, korrigeeritud HR = 1, 56; 95% CI = 1, 08... 2, 26; p=0, 018).